| (CCTG) CRC.10 / NRG-GI008 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) | Dr Shivani Dadwal | Open to recruitment | NCT05174169 |
| (CCTG) GA.4 | A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma | Dr Oren Levine | Open to recruitment | NCT06043427 |
| (CCTG) HE.2 / SLIDE-HCC | A Phase II Study of STRIDE (durvalumab + tremelimumab) with Lenvatinib versus STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC) | Dr Shivani Dadwal | Suspended/On hold | NCT06880523 |
| (HHS) DARTS | Radiation Therapy followed by Durvalumab / Tremelimumab And Surgery versus Radiation Therapy followed by Surgery for Resectable Hepatocellular Carcinoma. A Randomized Window of Opportunity Trial (DARTS) | Dr Pablo Serrano | Open to recruitment | NCT07027436 |
| (UHN) OZUHN-013 / DORA | Durvalumab and Oleclumab in Resectable PDAC: A Window of Opportunity Study (DORA Trial) | Dr Pablo Serrano | Open to recruitment | NCT06060405 |
Find a Trial
Contact Us